Polaryx Therapeutics (PLYX) Assets (2024 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Assets of $3.5 million for Q1 2026, down 32.26% quarter-over-quarter from $5.2 million in Q4 2025.

Polaryx Therapeutics (PLYX) Assets (2024 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Assets for 3 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Assets changed N/A year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (changed N/A YoY), while the FY2025 annual figure was $5.2 million, up 3.38% from the prior year.
Assets retreated to $3.5 million in Q1 2026 per PLYX's latest filing, from $5.2 million in the prior quarter.
Across five years, Assets topped out at $5.2 million in Q4 2025 and bottomed at $3.5 million in Q1 2026.
Historically, Assets has averaged $4.6 million across 3 years, with a median of $5.0 million in 2024.
On a YoY basis, Assets climbed as much as 3.38% in 2025 and fell as far as 3.38% in 2025.
Polaryx Therapeutics' Assets stood at $5.0 million in 2024, then advanced by 3.38% to $5.2 million in 2025, then sank by 32.26% to $3.5 million in 2026.
Business Quant data shows PLYX's Assets at $3.5 million in Q1 2026, $5.2 million in Q4 2025, and $5.0 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn	10.03 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn	10.96 Bn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn	9.18 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn	5.56 Bn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	25.60 Bn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	2.10 Bn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	19.82 Bn
10	Polaryx Therapeutics	101.38 Mn	89.84 Mn	-	11.81 Mn

Download Data